Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of HRS9531 in obese women with polycystic ovary syndrome
CTR20243161Phase 2Active
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Sep 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of HRS9531 in polycystic ovary syndrome (PCOS), obesity, sponsored by Fujian Shengdi Pharmaceuticals. Started Sep 2024; status: active.
02
Drugs
HRS9531
03
Conditions
polycystic ovary syndrome (PCOS)obesity
Beyond the preview
Go deeper on CTR20243161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243161.